Connection

Robert Grubb to Prostate-Specific Antigen

Back to Details
This is a "connection" page, showing publications Robert Grubb has written about Prostate-Specific Antigen.
Robert Grubb
Connection Strength
2.562
Prostate-Specific Antigen
  1. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 2008 Dec; 102(11):1524-30.
    View in: PubMed
    Score: 0.302
  2. The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer. Nat Clin Pract Urol. 2007 Nov; 4(11):605-14.
    View in: PubMed
    Score: 0.280
  3. Can preoperative PSA doubling time and PSA velocity predict outcomes following radical prostatectomy? Nat Clin Pract Urol. 2006 Jun; 3(6):306-7.
    View in: PubMed
    Score: 0.254
  4. Risk of Prostate Cancer-related Death Following a Low PSA Level in the PLCO Trial. Cancer Prev Res (Phila). 2020 04; 13(4):367-376.
    View in: PubMed
    Score: 0.163
  5. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int. 2019 05; 123(5):854-860.
    View in: PubMed
    Score: 0.150
  6. Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy. Eur Urol Oncol. 2018 06; 1(2):143-148.
    View in: PubMed
    Score: 0.145
  7. Prostate Cancer: Update on Early Detection and New Biomarkers. Mo Med. 2018 Mar-Apr; 115(2):132-134.
    View in: PubMed
    Score: 0.143
  8. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017 Feb 15; 123(4):592-599.
    View in: PubMed
    Score: 0.131
  9. Earlier prostate-specific antigen testing in African American men--Clinical support for the recommendation. Urol Oncol. 2015 Jul; 33(7):330.e9-17.
    View in: PubMed
    Score: 0.118
  10. Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer. 2013 Jun 15; 119(12):2223-9.
    View in: PubMed
    Score: 0.102
  11. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012 Jan 18; 104(2):125-32.
    View in: PubMed
    Score: 0.093
  12. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol. 2011 Feb 01; 29(4):355-61.
    View in: PubMed
    Score: 0.086
  13. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009 Mar 26; 360(13):1310-9.
    View in: PubMed
    Score: 0.077
  14. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2009 Mar; 18(3):748-51.
    View in: PubMed
    Score: 0.077
  15. Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer. 2007 Apr 15; 109(8):1689-95.
    View in: PubMed
    Score: 0.067
  16. Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology. 2006 Aug; 68(2):352-6.
    View in: PubMed
    Score: 0.064
  17. Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml. J Urol. 2005 Apr; 173(4):1116-20.
    View in: PubMed
    Score: 0.058
  18. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst. 2005 Mar 16; 97(6):433-8.
    View in: PubMed
    Score: 0.058
  19. Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States. J Urol. 2016 Oct; 196(4):1096-104.
    View in: PubMed
    Score: 0.032
  20. Evaluation of 3 T pelvic MRI imaging in prostate cancer patients receiving post-prostatectomy IMRT. World J Urol. 2015 Jan; 33(1):69-75.
    View in: PubMed
    Score: 0.027
  21. Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans? Urol Oncol. 2014 Jan; 32(1):34.e9-18.
    View in: PubMed
    Score: 0.025
  22. Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer Epidemiol. 2012 Dec; 36(6):e401-6.
    View in: PubMed
    Score: 0.025
  23. Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control. 2008 Dec; 19(10):1267-76.
    View in: PubMed
    Score: 0.018
  24. Patient selection determines the prostate cancer yield of dynamic contrast-enhanced magnetic resonance imaging-guided transrectal biopsies in a closed 3-Tesla scanner. BJU Int. 2008 Jan; 101(2):181-5.
    View in: PubMed
    Score: 0.017
  25. Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer. BJU Int. 2007 May; 99(5):1041-6.
    View in: PubMed
    Score: 0.017
  26. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int. 2007 Apr; 99(4):775-9.
    View in: PubMed
    Score: 0.017
  27. Results of compliance with prostate cancer screening guidelines. J Urol. 2005 Aug; 174(2):668-72; discussion 672.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.